EZH2 expression is associated with high proliferation rate and aggressive tumor subgroups in cutaneous melanoma and cancers of the endometrium, prostate, and breast.

By Ingeborg M. Bachmann, O. Halvorsen, K. Collett, I. Stefansson, O. Straume, S. Haukaas, H. Salvesen, A. Otte, L. Akslen. Journal of Clinical Oncology, 2006

847 citations recorded by the source corpus.

Subfields: Molecular Biology, Pulmonary and Respiratory Medicine

View Paper: https://www.semanticscholar.org/paper/8af118764c937526c86523e9ba9327f81f36f353

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Molecular Biology

In Pulmonary and Respiratory Medicine

Arul M. Chinnaiyan

Citations in the corpus

Molecular genetics of prostate cancer: new prospects for old challenges. (2010, background): “The Polycomb group gene EZH2 encodes a histone lysine methyltransferase that is frequently up-regulated in advanced prostate cancer, in some cases through gene amplification (Varambally et al. 2002; Saramaki et al. 2006), and is associated with aggressive tumors (Bachmann et al. 2006).”
Repression of E-cadherin by the polycomb group protein EZH2 in cancer (2008, background): “, 2004) melanoma (Bachmann et al., 2006), bladder cancer (Weikert et al.”
Epigenetic Modifications as Therapeutic Targets (2010, background): “EZH2 expression is an independent prognostic marker that is correlated with the aggressiveness of prostate, breast and endometrial cancer”
Ezh1 and Ezh2 maintain repressive chromatin through different mechanisms (2008, result): “Previous studies using immunohistochemistry (IHC) indicated that Ezh2 is barely detectable in normal adult tissues (Bachmann et al., 2006), although similar analyses with Ezh1 have not been reported.”